finance

Sanofi lowers Q3 sales figures from 2015

pharmafile | October 13, 2016 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Cipro, Plavix, Sanofi, financial results 

Sanofi lowered its aggregate sales figure for Q3 2016 from €9.59 billion to €9.46 billion ahead of the release of its third-quarter results for the year, expected on 28 October.

The company cites the rise of generic alternatives that are muscling in on its business as one of the reasons for the revision, highlighting in particular its cardiovascular drug Plavix (clopidogrel) which has seen its sales neutered by the appearance of a number of generic counterparts in Japan since June 2015; the company noted that sales in the region had fallen 59% from €I77 million in Q3 2015 to €93 million in the second-quarter of this year.

Hit hard by the competition generated by generics on the market, Sanofi announced it will also take a charge of $100 million in the settlement of litigation due to the launch of a generic equivalent of Bayer’s Cipro (ciprofloxacin) antibiotic.

The company has also reclassified €136 million in product sales from other manufacturers at its Vaxserve vaccines supply and services unit as other revenues.

However, it was not all bad news, as the company’s sales in Venezuela rose to €24 million this year versus €6 million in 2015’s second-quarter.

Matt Fellows

Related Content

Bayer and Aignostics to collaborate for AI oncology research

Bayer and Aignostics have announced that they have entered into a strategic collaboration for several …

Sanofi shares phase 2b results for dermatitis treatment

Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …

Sanofi to acquire Inhibrx for approximately $1.7bn

Sanofi and Inhibrx, Inc have announced that they have entered into a definitive agreement for …

Latest content